The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Heron Therapeutics Inc. (HRTX) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.54, or -12.03%, to $3.95. Volume reached 14,450 shares, with price reaching a high of $4.01 and a low of $3.8801. Yahoo Finance discussed the stock recently as it posted Heron Therapeutics Announces U.S. FDA Approval of APONVIE™ (HTX-019) for the Prevention of Postoperative Nausea and Vomiting (PONV).
The company is listed on the NASDAQ and operates within the Biotechnology industry segment. At the end of the last regular session, the stock closed at $4.01 and fluctuated between $4.4180 as its day high and $3.9800 as its day low. The current market capitalization of Heron Therapeutics Inc. is $445.63M. A total of 2.71 million shares were traded on the day, compared to an average of 3.39M shares.
Furthermore, investors take into consideration insider trades when predicting a stock’s future trajectory. During the recent three months, HRTX has seen 10 BUY and 5 SELL insider trades, representing the acquisition of 39,695 and the disposition of 12,115 shares. Over the last 12 months, there were 44 BUYs and 23 SELLs from insiders. Insiders purchased 184,622 shares during that period but sold 40,958.
In the most recent transaction, MANHARD KIMBERLY sold 1,504 shares of HRTX for 4.76 per share on May 03. After the transaction, the EVP, Drug Development now owns 10,872 company shares. In a previous transaction on Dec 21, Christian Waage sold 300 shares at 9.73 per share. HRTX shares that Director owns now total 3,200.
Among the insiders who sold shares, Johnson Craig A disposed of 250 shares on Dec 21 at a per-share price of $9.73. This resulted in the Director holding 2,840 shares of HRTX after the transaction.
It has been observed that price targets are rarely accurate, but they can exert some influence from time to time, and are often accepted as valuable in the market. According to analysts who have offered 12-month price targets for HRTX in the last 3 months, the mean price target is $13.42 with high estimates of $30.00 and low estimates of $5.50. In terms of 52-week highs and lows, HRTX has a high of $12.79 and a low of $2.19.
As of this writing, HRTX has an earnings estimate of $-0.39 per share for the current quarter. EPS was calculated based on a consensus of 3 estimates, with a high estimate of $-0.31 per share and a lower estimate of $-0.44. The company reported an EPS of $-0.55 in the last quarter, which was -10% lower than expectations of $-0.5.
Balance Sheet Annually/Quarterly
An equity investor’s investment can be viewed on a balance sheet by looking at what assets and liabilities the company has. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Currently, 6 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for HRTX is Overweight with a score of 4.80. A total of 6 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.